RXRX Quote, Financials, Valuation and Earnings

Intuitive Surgical has a net margin of -367.46% compared to Recursion Pharmaceuticals's net margin of 27.73%. Recursion Pharmaceuticals's return on equity of -78.32% beat Intuitive Surgical's return on equity of 15.9%.

Recursion Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 41.02%. On the other hand Intuitive Surgical has an analysts' consensus of $556.42 which suggests that it could grow by 5.54%. Given that Recursion Pharmaceuticals has higher upside potential than Intuitive Surgical, analysts believe Recursion Pharmaceuticals is more attractive than Intuitive Surgical.

Recursion Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.383, suggesting its more volatile than the S&P 500 by 38.272%.

Recursion Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Recursion Pharmaceuticals pays -- of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend.

Recursion Pharmaceuticals quarterly revenues are $26.1M, which are smaller than Intuitive Surgical quarterly revenues of $2B. Recursion Pharmaceuticals's net income of -$95.8M is lower than Intuitive Surgical's net income of $565.1M. Notably, Recursion Pharmaceuticals's price-to-earnings ratio is -- while Intuitive Surgical's PE ratio is 84.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Recursion Pharmaceuticals is 26.59x versus 24.17x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -367.46% compared to Recursion Pharmaceuticals's net margin of -49.65%. Recursion Pharmaceuticals's return on equity of -78.32% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Recursion Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 41.02%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 620.92%. Given that NovaBay Pharmaceuticals has higher upside potential than Recursion Pharmaceuticals, analysts believe NovaBay Pharmaceuticals is more attractive than Recursion Pharmaceuticals.

Recursion Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Recursion Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Recursion Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Recursion Pharmaceuticals quarterly revenues are $26.1M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Recursion Pharmaceuticals's net income of -$95.8M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Recursion Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Recursion Pharmaceuticals is 26.59x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -367.46% compared to Recursion Pharmaceuticals's net margin of -2357.27%. Recursion Pharmaceuticals's return on equity of -78.32% beat Palatin Technologies's return on equity of --.

Recursion Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 41.02%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1652.58%. Given that Palatin Technologies has higher upside potential than Recursion Pharmaceuticals, analysts believe Palatin Technologies is more attractive than Recursion Pharmaceuticals.

Recursion Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

Recursion Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Recursion Pharmaceuticals pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Recursion Pharmaceuticals quarterly revenues are $26.1M, which are larger than Palatin Technologies quarterly revenues of $350K. Recursion Pharmaceuticals's net income of -$95.8M is lower than Palatin Technologies's net income of -$7.8M. Notably, Recursion Pharmaceuticals's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Recursion Pharmaceuticals is 26.59x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Revance Therapeutics has a net margin of -367.46% compared to Recursion Pharmaceuticals's net margin of -63.65%. Recursion Pharmaceuticals's return on equity of -78.32% beat Revance Therapeutics's return on equity of --.

Recursion Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 41.02%. On the other hand Revance Therapeutics has an analysts' consensus of $7.64 which suggests that it could grow by 148.77%. Given that Revance Therapeutics has higher upside potential than Recursion Pharmaceuticals, analysts believe Revance Therapeutics is more attractive than Recursion Pharmaceuticals.

Recursion Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Revance Therapeutics has a beta of 0.815, suggesting its less volatile than the S&P 500 by 18.478%.

Recursion Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Revance Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Recursion Pharmaceuticals pays -- of its earnings as a dividend. Revance Therapeutics pays out -- of its earnings as a dividend.

Recursion Pharmaceuticals quarterly revenues are $26.1M, which are smaller than Revance Therapeutics quarterly revenues of $59.9M. Recursion Pharmaceuticals's net income of -$95.8M is lower than Revance Therapeutics's net income of -$38.1M. Notably, Recursion Pharmaceuticals's price-to-earnings ratio is -- while Revance Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Recursion Pharmaceuticals is 26.59x versus 1.16x for Revance Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.